Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

BeiGene Ltd Stock Research

BGNE

185.56USD-4.82(-2.53%)Market Closed
Watchlist

Market Summary

USD185.56-4.82
Market Closed
-2.53%

BGNE Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

BGNE Stock Price

BGNE RSI Chart

BGNE Valuation

Market Cap

255.4B

Price/Earnings (Trailing)

-147.41

Price/Sales (Trailing)

141.03

EV/EBITDA

-162.77

Price/Free Cashflow

-115.3

BGNE Price/Sales (Trailing)

BGNE Profitability

EBT Margin

-120.53%

Return on Equity

-46.11%

Return on Assets

-32.18%

Free Cashflow Yield

-0.87%

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

1.8B

Revenue Y/Y

74.27%

Revenue Q/Q

32.93%

BGNE Earnings

Earnings (TTM)

-1.7B

Earnings Y/Y

32.63%

Earnings Q/Q

-9.39%

Price Action

52 Week Range

124.46280.62
(Low)(High)

Last 7 days

-11.2%

Last 30 days

-6.5%

Last 90 days

3.2%

Trailing 12 Months

40.8%

BGNE Financial Health

Current Ratio

3.75

BGNE Investor Care

Shares Dilution (1Y)

2.98%

Diluted EPS (TTM)

-1.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BGNE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-07-31
Lee Chan Henry
sold
-171,059
216
-791
svp, general counsel
2023-07-03
Wang Julia Aijun
sold
-84,747
179
-472
chief financial officer
2023-06-26
Wang Lai
sold
-201,567
181
-1,108
global head of r&d
2023-06-26
Wu Xiaobin
sold
-272,636
182
-1,495
president, coo & gm china
2023-06-23
Wang Julia Aijun
sold
-153,594
182
-840
chief financial officer
2023-06-23
Sanders Corazon (Corsee) D.
sold
-105,381
182
-578
-
2023-06-20
Wang Lai
sold
-254,955
192
-1,325
global head of r&d
2023-06-20
Wu Xiaobin
sold
-337,356
192
-1,753
president, coo & gm china
2023-06-20
Wang Julia Aijun
sold
-36,583
192
-190
chief financial officer
2023-06-15
BAKER BROS. ADVISORS LP
acquired
-
-
51,688
-

1–10 of 50

Which funds bought or sold BGNE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
1,058
165,000
184,000
-%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
-707
3,388
-%
2023-08-24
Alberta Investment Management Corp
new
-
486,224
486,224
-%
2023-08-22
Old North State Trust, LLC
sold off
-100
-4,000
-
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-258,636
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
2.47
-55,140
304,654
-%
2023-08-21
BOKF, NA
sold off
-100
-3,017
-
-%
2023-08-16
Thomas J. Herzfeld Advisors, Inc.
unchanged
-
-819
3,923
-%
2023-08-16
Nuveen Asset Management, LLC
added
163
5,131,560
9,485,560
-%
2023-08-15
PIN OAK INVESTMENT ADVISORS INC
new
-
1,000
1,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying BGNE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BGNE
No. of Funds

Schedule 13G FIlings of BeiGene

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 05, 2023
baker bros. advisors lp
11.2%
152,522,377
SC 13D/A
Feb 14, 2023
hhlr advisors, ltd.
10.9%
147,043,058
SC 13D/A
Feb 13, 2023
capital international investors
8.2%
110,215,170
SC 13G/A
Feb 10, 2023
oyler john
5.1%
70,026,397
SC 13G/A
Aug 16, 2022
hhlr advisors, ltd.
10.9%
147,035,258
SC 13D/A
Feb 14, 2022
oyler john
5.1%
69,558,605
SC 13G/A
Feb 11, 2022
capital international investors
7.8%
104,036,177
SC 13G/A
Feb 11, 2022
beigene, ltd.
5.1%
69,558,605
SC 13G/A
Feb 11, 2022
invesco ltd.
5.6%
39,028,821
SC 13G
Feb 09, 2022
fmr llc
-
0
SC 13G/A

Recent SEC filings of BeiGene

View All Filings
Date Filed Form Type Document
Sep 21, 2023
8-K
Current Report
Sep 19, 2023
8-K
Current Report
Aug 29, 2023
8-K
Current Report
Aug 02, 2023
10-Q
Quarterly Report
Aug 02, 2023
4
Insider Trading
Aug 02, 2023
8-K
Current Report
Jul 31, 2023
144
Notice of Insider Sale Intent
Jul 24, 2023
8-K
Current Report
Jul 11, 2023
8-K
Current Report
Jul 06, 2023
4
Insider Trading

Peers (Alternatives to BeiGene)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
272.0B
56.0B
4.92% 10.10%
31.31
4.85
-2.31% -31.27%
255.4B
1.8B
-6.48% 40.79%
-147.41
141.03
69.45% 14.65%
90.7B
9.5B
0.47% 27.06%
26.94
9.54
13.83% 5.33%
89.1B
12.7B
0.25% 21.32%
20.72
7.03
-10.94% -24.40%
21.9B
1.2B
-7.51% -11.32%
-20.56
17.67
39.94% -8.44%
11.1B
1.0B
0.34% 12.49%
-12.27
11.1
20.15% -79.16%
10.8B
2.1B
0.39% 13.09%
12.38
5.11
18.01% 38.16%
MID-CAP
3.0B
225.6M
-1.27% -20.90%
-5.46
13.42
-2.11% 21.02%
2.7B
-
-16.94% 136.35%
-8.34
-
- -28.88%
2.7B
402.9M
-1.32% -6.38%
-3.71
6.64
20.50% -42.46%
2.4B
27.2M
9.81% -39.54%
-3.22
87.12
- -14.43%
SMALL-CAP
3.1B
-
-13.94% -37.40%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-14.75% 0.41%
11.19
4.27
77.72% 112.02%
295.4M
152.5M
-5.54% 48.60%
39.66
1.94
127.84% 103.41%
28.4M
-
-5.44% 3918.75%
-0.62
-
- -31.51%

BeiGene News

Best Stocks
Challenges and Potential of Generic Drug Companies in Improving ....
Best Stocks,
15 hours ago
Investing.com México

Returns for BGNE

Cumulative Returns on BGNE

30.1%


7-Year Cumulative Returns

1.5%


5-Year Cumulative Returns

-13.1%


3-Year Cumulative Returns

Risks for BGNE

What is the probability of a big loss on BGNE?

100%


Probability that BeiGene stock will be more than 20% underwater in next one year

75.4%


Probability that BeiGene stock will be more than 30% underwater in next one year.

33.9%


Probability that BeiGene stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BGNE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.

Drawdowns

Financials for BeiGene

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue16.3%1,810,785,0001,557,096,0001,415,921,0001,249,805,0001,068,617,000877,037,0001,176,283,0001,062,404,000947,044,000862,687,000308,874,000265,666,000224,727,000402,438,000428,212,000429,990,000434,051,000243,509,000198,220,000157,724,000323,735,000
  S&GA Expenses4.9%1,375,409,0001,311,778,0001,277,852,0001,255,369,0001,201,704,0001,102,590,000990,123,000891,831,000783,441,000675,201,000600,176,000535,321,000479,486,000437,685,000388,249,000317,385,000261,203,000224,115,000195,385,000150,310,000117,131,000
  R&D Expenses2.7%1,703,734,0001,659,177,0001,640,508,0001,624,970,0001,550,544,0001,528,428,0001,459,239,0001,384,291,0001,381,424,0001,311,301,0001,294,877,0001,222,599,0001,110,497,0001,053,289,000927,338,000901,543,000812,165,000747,656,000679,005,000512,881,000452,951,000
EBITDA100.0%--1,748,613,000-1,842,279,000-2,025,714,000-1,926,567,000-1,870,492,000-1,407,888,000-1,309,765,000-1,313,727,000-1,168,144,000-1,584,407,000-1,478,361,000-1,356,700,000-1,105,126,000-915,838,000------
EBITDA Margin100.0%--1.12-1.30-1.62-1.80-2.13-1.20-1.23-1.39-1.35-5.13-5.56-6.04-2.75-2.14------
Interest Expenses6.2%62,064,00058,425,00052,480,00029,779,00014,790,000-1,507,000-15,757,000-16,461,000-14,845,000-8,871,0001,998,0006,746,0009,566,00011,344,0009,131,00015,519,00017,866,00016,872,00013,947,0007,470,0001,132,000
Earnings Before Taxes10.1%-1,686,605,000-1,876,727,000-1,961,037,000-2,116,876,000-1,998,716,000-1,921,702,000-1,438,588,000-1,333,760,000-1,335,722,000-1,192,944,000-1,618,194,000-1,516,552,000-1,393,389,000-1,139,421,000-943,586,000-838,506,000-671,593,000-748,851,000-689,829,000-508,940,000-249,753,000
EBT Margin100.0%--1.21-1.38-1.69-1.87-2.19-1.22-1.26-1.41-1.38-5.24-5.71-6.20-2.83-2.20------
Net Income9.6%-1,732,459,000-1,917,048,000-2,003,815,000-2,149,158,000-2,029,716,000-1,948,594,000-1,457,816,000-1,339,883,000-1,326,993,000-1,178,707,000-1,599,226,000-1,514,542,000-1,396,675,000-1,145,927,000-948,628,000-828,822,000-665,496,000-736,813,000-673,769,000-504,837,000-243,420,000
Net Income Margin100.0%--1.23-1.42-1.72-1.86-2.18-1.20-1.22-1.39-1.35-5.17-5.69-6.20-2.84-2.22------
Free Cashflow100.0%--2,229,721,000-1,822,053,000-2,005,322,000-1,897,517,000-1,926,065,000-1,561,665,000-1,305,870,000-1,118,036,000-954,786,000-1,400,969,000-1,316,591,000-1,237,554,000-1,009,555,000-839,881,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-3.8%5,7295,9576,3796,7267,3788,0218,5365,2865,5245,8215,6015,5663,9034,0671,6121,8812,1502,1722,2502,4091,654
  Current Assets-6.4%4,4014,7045,2075,7496,3466,9487,6144,4334,7995,1414,9614,9663,3923,5951,1731,4361,7561,7971,9442,1801,517
    Cash Equivalents-3.6%3,4103,5393,8704,1974,5314,3474,3831,3831,7761,9021,3821,4641,3451,957621857919764741643438
  Inventory8.2%32129728229126224624315111873.0089.0036.0033.0029.0029.0038.0049.0013.0016.0020.006.00
  Net PPE11.5%1,03292584668263362558845139537435829125824024222621319815711191.00
  Goodwill----------------0.000.000.000.000.000.00
Liabilities7.3%1,9301,7991,9962,0712,0762,1362,4031,9291,9171,8171,7321,2701,3571,240634587579550496425427
  Current Liabilities12.0%1,4051,2551,4691,4111,3981,3761,6001,3041,2421,1131,075646551452310266272239246188186
    LT Debt, Current-78.2%4211,9352,2694412,5504074282,8502,80740533550.0026.0011.00-1.009.009.009.009.009.00
    LT Debt, Non Current0.5%2072062092081852021,2882011951,2651,19815213182.0058010484.0077.0041.0041.0051.00
Shareholder's Equity-8.6%3,7994,1574,3834,6555,1975,7746,1333,2523,5263,9273,8034,2972,5462,8279401,2941,5711,6231,7541,9831,227
  Retained Earnings-5.1%-7,809-7,428-7,080-6,635-5,971-5,400-5,076-4,380-3,966-3,486-3,552-3,080-2,654-2,319-1,955-1,567-1,260-1,174-1,007-738-594
  Additional Paid-In Capital0.9%11,75211,64511,54111,45211,35711,26811,1917,7257,5617,4877,4157,3685,2005,1382,9262,8612,8142,7772,7452,7101,805
Shares Outstanding1.0%1,3761,3631,3561,3501,3361,3321,3351,2061,1941,1891,1911,1491,0101,005801781776775721703699
Minority Interest------------9.0010.0015.0016.0016.0017.0014.0014.0013.0013.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations4.7%-1,737-1,823-1,496-1,686-1,620-1,660-1,298-1,123-973-816-1,283-1,218-1,137-920-750-676-544-615-547-260-121
  Share Based Compensation7.1%33531330328827726024122721019118317215914613412211096.0087.0078.0066.00
Cashflow From Investing-53.3%5171,1081,0771,148966559641445-1,079-1,761-3,168-3,105-1,355-73355479187.00-70.84-637-919-829
Cashflow From Financing666.1%156-27.57-18.973,4763,4653,5183,6375782,4632,5085,2034,8792,9102,84586.0092.009389701,6911,6851,153

BGNE Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues    
Total revenues$ 595,261$ 341,572$ 1,043,062$ 648,198
Expenses    
Cost of sales - product95,99071,173177,779136,410
Research and development422,764378,207831,348768,122
Selling, general and administrative395,034331,403723,533625,976
Amortization of intangible assets188188375376
Total expenses913,976780,9711,733,0351,530,884
Loss from operations(318,715)(439,399)(689,973)(882,686)
Interest income, net15,07011,43131,08621,502
Other expense, net(63,818)(129,617)(45,515)(117,650)
Loss before income taxes(367,463)(557,585)(704,402)(978,834)
Income tax expense13,6748,14125,16622,090
Net loss$ (381,137)$ (565,726)$ (729,568)$ (1,000,924)
Net loss per share, basic (in dollars per share)$ (0.28)$ (0.42)$ (0.54)$ (0.75)
Net loss per share, diluted (in dollars per share)$ (0.28)$ (0.42)$ (0.54)$ (0.75)
Weighted-average shares outstanding—basic (in shares)1,360,224,3771,336,463,0261,357,211,3081,334,252,648
Weighted-average shares outstanding - diluted (in shares)1,360,224,3771,336,463,0261,357,211,3081,334,252,648
Net loss per American Depositary Share ("ADS") basic (in dollars per share)$ (3.64)$ (5.50)$ (6.99)$ (9.75)
Net loss per American Depositary Share ("ADS") diluted (in dollars per share)$ (3.64)$ (5.50)$ (6.99)$ (9.75)
Weighted-average ADSs outstanding - basic (in shares)104,632,644102,804,848104,400,870102,634,819
Weighted-average ADSs outstanding - diluted (in shares)104,632,644102,804,848104,400,870102,634,819
Product revenue, net    
Revenues    
Total revenues$ 553,745$ 304,511$ 964,036$ 566,084
Collaboration revenue    
Revenues    
Total revenues$ 41,516$ 37,061$ 79,026$ 82,114

BGNE Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS
¥ in Thousands, $ in Thousands
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Current assets:  
Cash and cash equivalents$ 3,410,368$ 3,869,564
Short-term restricted cash9,693196
Short-term investments105,693665,251
Accounts receivable, net299,282173,168
Inventories321,333282,346
Prepaid expenses and other current assets255,050216,553
Total current assets4,401,4195,207,078
Long-term restricted cash1,5135,277
Property, plant and equipment, net1,031,938845,946
Operating lease right-of-use assets99,422109,960
Intangible assets, net46,89540,616
Other non-current assets147,549170,413
Total non-current assets1,327,3171,172,212
Total assets5,728,7366,379,290
Current liabilities:  
Accounts payable266,975294,781
Accrued expenses and other payables454,950467,352
Deferred revenue, current portion159,034213,861
Tax payable17,07425,189
Operating lease liabilities, current portion23,50824,041
Research and development cost share liability, current portion62,516114,335
Short-term debt421,052328,969
Total current liabilities1,405,1091,468,528
Non-current liabilities:  
Long-term bank loans207,426209,148
Deferred revenue, non-current portion24,27642,026
Operating lease liabilities, non-current portion25,82134,517
Deferred tax liabilities15,65215,996
Research and development cost share liability, non-current portion208,775179,625
Other long-term liabilities43,11846,095
Total non-current liabilities525,068527,407
Total liabilities1,930,1771,995,935
Commitments and contingencies
Equity:  
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,376,251,336 and 1,356,140,180 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively137135
Additional paid-in capital11,752,01911,540,979
Accumulated other comprehensive loss(143,687)(77,417)
Accumulated deficit(7,809,910)(7,080,342)
Total equity3,798,5594,383,355
Total liabilities and equity$ 5,728,736$ 6,379,290
John V. Oyler
8200
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.